Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2020-03-03

AUTHORS

Mitchell E. Gross, David B. Agus, Tanya B. Dorff, Jacek K. Pinski, David I. Quinn, Olga Castellanos, Patrick Gilmore, Jean C. Shih

ABSTRACT

PurposeMonoamine oxidase A (MAOA) influences prostate cancer growth and metastasis in pre-clinical models. We examined effects of phenelzine (a monoamine oxidase inhibitor) in patients with biochemical recurrent castrate-sensitive prostate cancer.Materials and methodsAn open-label single arm clinical trial enrolled subjects with biochemical recurrent prostate cancer defined by PSA ≥ 0.4 ng/ml (post prostatectomy) or PSA ≥ 2 ng/ml above nadir (post-radiation therapy); no evidence of metastasis on imaging; and normal androgen levels. Subjects received phenelzine 30 mg orally twice daily. Mood symptoms were assessed with the hospital anxiety depression score (HADS) questionnaire. The primary endpoint was the proportion of patients who achieved a PSA decline of ≥50% from baseline.ResultsCharacteristics of the 20 eligible patients enrolled included: mean ± SD age 66.9 ± 4.8 years and PSA 4.7 ± 5.8 ng/dl. Maximal PSA declines ≥30% and ≥50% were observed in 25% (n = 5/20) and 10% (n = 2/20) of subjects, respectively. At 12 weeks, 17 subjects remained on treatment with PSA declines ≥30% and ≥50% of 24% (n = 4/17) and 6% (n = 1/17), respectively. Common toxicities observed included dizziness (grade 1 = 45%, grade 2 = 35%), hypertension (grade ≥ 2 = 30%), and edema (grade 1 = 25%, grade 2 = 10%). There was one episode of grade 4 hypertension (cycle 4) and two episodes of grade 3 syncope (cycle 12 and cycle 14) requiring treatment discontinuation. HADS questionnaires demonstrated a significant decrease in anxiety with no change in depressive symptoms on treatment.ConclusionsPhenelzine demonstrated efficacy in patients with biochemical recurrent castrate-sensitive prostate cancer. Most treatment-related toxicities were mild, but rare significant and reversible cardiovascular toxicities were observed. Therapies directed at MAOA may represent a new avenue for treatment in patients with recurrent prostate cancer. More... »

PAGES

61-68

Identifiers

URI

http://scigraph.springernature.com/pub.10.1038/s41391-020-0211-9

DOI

http://dx.doi.org/10.1038/s41391-020-0211-9

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1125322716

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/32123315


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adenocarcinoma", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers, Tumor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Monoamine Oxidase Inhibitors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Recurrence, Local", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Staging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Phenelzine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostate-Specific Antigen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prostatic Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "Lawrence J. Ellison Institute for Transformative Medicine, University of Southern California, Los Angeles, CA, USA", 
            "Department of Medicine, University of Southern California, Los Angeles, CA, USA", 
            "Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gross", 
        "givenName": "Mitchell E.", 
        "id": "sg:person.0623540223.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0623540223.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "Lawrence J. Ellison Institute for Transformative Medicine, University of Southern California, Los Angeles, CA, USA", 
            "Department of Medicine, University of Southern California, Los Angeles, CA, USA", 
            "Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Agus", 
        "givenName": "David B.", 
        "id": "sg:person.01130633732.24", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01130633732.24"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "Department of Medicine, University of Southern California, Los Angeles, CA, USA", 
            "Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dorff", 
        "givenName": "Tanya B.", 
        "id": "sg:person.01007666002.23", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007666002.23"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "Department of Medicine, University of Southern California, Los Angeles, CA, USA", 
            "Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pinski", 
        "givenName": "Jacek K.", 
        "id": "sg:person.0600562331.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0600562331.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "Department of Medicine, University of Southern California, Los Angeles, CA, USA", 
            "Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Quinn", 
        "givenName": "David I.", 
        "id": "sg:person.01013134010.15", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013134010.15"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Lawrence J. Ellison Institute for Transformative Medicine, University of Southern California, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "Lawrence J. Ellison Institute for Transformative Medicine, University of Southern California, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Castellanos", 
        "givenName": "Olga", 
        "id": "sg:person.015566147707.12", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015566147707.12"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Lawrence J. Ellison Institute for Transformative Medicine, University of Southern California, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "Lawrence J. Ellison Institute for Transformative Medicine, University of Southern California, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gilmore", 
        "givenName": "Patrick", 
        "id": "sg:person.010167317465.06", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010167317465.06"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA, USA", 
          "id": "http://www.grid.ac/institutes/grid.42505.36", 
          "name": [
            "Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA", 
            "Department of Integrative Anatomical Sciences, University of Southern California, Los Angeles, CA, USA", 
            "Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shih", 
        "givenName": "Jean C.", 
        "id": "sg:person.07360615242.02", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07360615242.02"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/nrn1883", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1004025765", 
          "https://doi.org/10.1038/nrn1883"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/s41388-018-0325-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1104267265", 
          "https://doi.org/10.1038/s41388-018-0325-x"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2020-03-03", 
    "datePublishedReg": "2020-03-03", 
    "description": "PurposeMonoamine oxidase A (MAOA) influences prostate cancer growth and metastasis in pre-clinical models. We examined effects of phenelzine (a monoamine oxidase inhibitor) in patients with biochemical recurrent castrate-sensitive prostate cancer.Materials and methodsAn open-label single arm clinical trial enrolled subjects with biochemical recurrent prostate cancer defined by PSA\u2009\u2265\u20090.4\u2009ng/ml (post prostatectomy) or PSA\u2009\u2265\u20092\u2009ng/ml above nadir (post-radiation therapy); no evidence of metastasis on imaging; and normal androgen levels. Subjects received phenelzine 30\u2009mg orally twice daily. Mood symptoms were assessed with the hospital anxiety depression score (HADS) questionnaire. The primary endpoint was the proportion of patients who achieved a PSA decline of \u226550% from baseline.ResultsCharacteristics of the 20 eligible patients enrolled included: mean\u2009\u00b1\u2009SD age 66.9\u2009\u00b1\u20094.8 years and PSA 4.7\u2009\u00b1\u20095.8\u2009ng/dl. Maximal PSA declines \u226530% and \u226550% were observed in 25% (n\u2009=\u20095/20) and 10% (n\u2009=\u20092/20) of subjects, respectively. At 12 weeks, 17 subjects remained on treatment with PSA declines \u226530% and \u226550% of 24% (n\u2009=\u20094/17) and 6% (n\u2009=\u20091/17), respectively. Common toxicities observed included dizziness (grade 1\u2009=\u200945%, grade 2\u2009=\u200935%), hypertension (grade \u2265\u20092\u2009=\u200930%), and edema (grade 1\u2009=\u200925%, grade 2\u2009=\u200910%). There was one episode of grade 4 hypertension (cycle 4) and two episodes of grade 3 syncope (cycle 12 and cycle 14) requiring treatment discontinuation. HADS questionnaires demonstrated a significant decrease in anxiety with no change in depressive symptoms on treatment.ConclusionsPhenelzine demonstrated efficacy in patients with biochemical recurrent castrate-sensitive prostate cancer. Most treatment-related toxicities were mild, but rare significant and reversible cardiovascular toxicities were observed. Therapies directed at MAOA may represent a new avenue for treatment in patients with recurrent prostate cancer.", 
    "genre": "article", 
    "id": "sg:pub.10.1038/s41391-020-0211-9", 
    "isAccessibleForFree": true, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2438805", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.5477093", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1119336", 
        "issn": [
          "1365-7852", 
          "1476-5608"
        ], 
        "name": "Prostate Cancer and Prostatic Diseases", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "24"
      }
    ], 
    "keywords": [
      "recurrent prostate cancer", 
      "biochemical recurrent prostate cancer", 
      "prostate cancer", 
      "open-label single-arm clinical trial", 
      "Most treatment-related toxicities", 
      "single-arm clinical trial", 
      "monoamine oxidase inhibitor phenelzine", 
      "normal androgen levels", 
      "Depression Score questionnaires", 
      "grade 4 hypertension", 
      "treatment-related toxicity", 
      "evidence of metastasis", 
      "proportion of patients", 
      "phase 2 trial", 
      "effects of phenelzine", 
      "arm clinical trial", 
      "pre-clinical models", 
      "PSA decline", 
      "eligible patients", 
      "common toxicities", 
      "primary endpoint", 
      "treatment discontinuation", 
      "HADS questionnaire", 
      "score questionnaire", 
      "cardiovascular toxicity", 
      "clinical trials", 
      "androgen levels", 
      "mood symptoms", 
      "depressive symptoms", 
      "patients", 
      "cancer growth", 
      "cancer", 
      "PSA", 
      "significant decrease", 
      "hypertension", 
      "phenelzine", 
      "metastasis", 
      "symptoms", 
      "treatment", 
      "trials", 
      "subjects", 
      "toxicity", 
      "episodes", 
      "questionnaire", 
      "dizziness", 
      "discontinuation", 
      "edema", 
      "syncope", 
      "ResultsCharacteristics", 
      "therapy", 
      "dl", 
      "baseline", 
      "endpoint", 
      "weeks", 
      "efficacy", 
      "anxiety", 
      "MAOA", 
      "years", 
      "proportion", 
      "new avenues", 
      "evidence", 
      "levels", 
      "decline", 
      "decrease", 
      "effect", 
      "changes", 
      "avenues", 
      "growth", 
      "model", 
      "materials"
    ], 
    "name": "Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer", 
    "pagination": "61-68", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1125322716"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1038/s41391-020-0211-9"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "32123315"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1038/s41391-020-0211-9", 
      "https://app.dimensions.ai/details/publication/pub.1125322716"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-10-01T06:47", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221001/entities/gbq_results/article/article_851.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1038/s41391-020-0211-9"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/s41391-020-0211-9'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/s41391-020-0211-9'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/s41391-020-0211-9'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/s41391-020-0211-9'


 

This table displays all metadata directly associated to this object as RDF triples.

270 TRIPLES      21 PREDICATES      115 URIs      105 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1038/s41391-020-0211-9 schema:about N0ecadb66ad9d48f79554241000712aa2
2 N10b069ff09d64e1ea087a6b64cc33795
3 N27ac0466813e4484a77731dfad77b7c3
4 N50e78ad5218140c5955b5adbeacb3898
5 N60d12dc01ca74ecdb35cbb1a50f2d6a6
6 N6147dc9d33124e08b3e0c5cf7b69ac48
7 N628a57780c9c46738bedd6f3c70ac083
8 N7001cd1a722142108b77d4b96915eccc
9 N719fe66593ac488a90ff44dfdff2cb1b
10 N76b36059dc1d4e45a04d388d7ed38ee6
11 N880c06bc8581472ab36404dd4d75f270
12 N90cfcb34c656455ebc7b21bc1806fcef
13 N9f95987868044268ab18694ed461b602
14 Nc3993d40cf0e42cb9174aec4067f32dd
15 Nc5525a2ad0f64c19b36d89150d3de688
16 Nc9398808799e4e57898c88b6e3411dfb
17 Nd9881e5a64bb460ca580213273b19440
18 Nf8863eea5ce14ca885cac8b0331327ea
19 anzsrc-for:11
20 anzsrc-for:1112
21 schema:author N7c88b1f77b4b46e685dfd4add99aba14
22 schema:citation sg:pub.10.1038/nrn1883
23 sg:pub.10.1038/s41388-018-0325-x
24 schema:datePublished 2020-03-03
25 schema:datePublishedReg 2020-03-03
26 schema:description PurposeMonoamine oxidase A (MAOA) influences prostate cancer growth and metastasis in pre-clinical models. We examined effects of phenelzine (a monoamine oxidase inhibitor) in patients with biochemical recurrent castrate-sensitive prostate cancer.Materials and methodsAn open-label single arm clinical trial enrolled subjects with biochemical recurrent prostate cancer defined by PSA ≥ 0.4 ng/ml (post prostatectomy) or PSA ≥ 2 ng/ml above nadir (post-radiation therapy); no evidence of metastasis on imaging; and normal androgen levels. Subjects received phenelzine 30 mg orally twice daily. Mood symptoms were assessed with the hospital anxiety depression score (HADS) questionnaire. The primary endpoint was the proportion of patients who achieved a PSA decline of ≥50% from baseline.ResultsCharacteristics of the 20 eligible patients enrolled included: mean ± SD age 66.9 ± 4.8 years and PSA 4.7 ± 5.8 ng/dl. Maximal PSA declines ≥30% and ≥50% were observed in 25% (n = 5/20) and 10% (n = 2/20) of subjects, respectively. At 12 weeks, 17 subjects remained on treatment with PSA declines ≥30% and ≥50% of 24% (n = 4/17) and 6% (n = 1/17), respectively. Common toxicities observed included dizziness (grade 1 = 45%, grade 2 = 35%), hypertension (grade ≥ 2 = 30%), and edema (grade 1 = 25%, grade 2 = 10%). There was one episode of grade 4 hypertension (cycle 4) and two episodes of grade 3 syncope (cycle 12 and cycle 14) requiring treatment discontinuation. HADS questionnaires demonstrated a significant decrease in anxiety with no change in depressive symptoms on treatment.ConclusionsPhenelzine demonstrated efficacy in patients with biochemical recurrent castrate-sensitive prostate cancer. Most treatment-related toxicities were mild, but rare significant and reversible cardiovascular toxicities were observed. Therapies directed at MAOA may represent a new avenue for treatment in patients with recurrent prostate cancer.
27 schema:genre article
28 schema:isAccessibleForFree true
29 schema:isPartOf N79bb311c1a114ef395727c4aa33765dd
30 Ndfe7193278b748d89b72fd1ef0f5244f
31 sg:journal.1119336
32 schema:keywords Depression Score questionnaires
33 HADS questionnaire
34 MAOA
35 Most treatment-related toxicities
36 PSA
37 PSA decline
38 ResultsCharacteristics
39 androgen levels
40 anxiety
41 arm clinical trial
42 avenues
43 baseline
44 biochemical recurrent prostate cancer
45 cancer
46 cancer growth
47 cardiovascular toxicity
48 changes
49 clinical trials
50 common toxicities
51 decline
52 decrease
53 depressive symptoms
54 discontinuation
55 dizziness
56 dl
57 edema
58 effect
59 effects of phenelzine
60 efficacy
61 eligible patients
62 endpoint
63 episodes
64 evidence
65 evidence of metastasis
66 grade 4 hypertension
67 growth
68 hypertension
69 levels
70 materials
71 metastasis
72 model
73 monoamine oxidase inhibitor phenelzine
74 mood symptoms
75 new avenues
76 normal androgen levels
77 open-label single-arm clinical trial
78 patients
79 phase 2 trial
80 phenelzine
81 pre-clinical models
82 primary endpoint
83 proportion
84 proportion of patients
85 prostate cancer
86 questionnaire
87 recurrent prostate cancer
88 score questionnaire
89 significant decrease
90 single-arm clinical trial
91 subjects
92 symptoms
93 syncope
94 therapy
95 toxicity
96 treatment
97 treatment discontinuation
98 treatment-related toxicity
99 trials
100 weeks
101 years
102 schema:name Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer
103 schema:pagination 61-68
104 schema:productId N07a1a09a0a4048edbb0d50640bf04a0f
105 Na34ad9ea6e304504b8229ca60fe7e36a
106 Ned4c8512305d4b69b471c08850da91ad
107 schema:sameAs https://app.dimensions.ai/details/publication/pub.1125322716
108 https://doi.org/10.1038/s41391-020-0211-9
109 schema:sdDatePublished 2022-10-01T06:47
110 schema:sdLicense https://scigraph.springernature.com/explorer/license/
111 schema:sdPublisher N19a40581acf6468caa65d1df94aa1970
112 schema:url https://doi.org/10.1038/s41391-020-0211-9
113 sgo:license sg:explorer/license/
114 sgo:sdDataset articles
115 rdf:type schema:ScholarlyArticle
116 N07a1a09a0a4048edbb0d50640bf04a0f schema:name pubmed_id
117 schema:value 32123315
118 rdf:type schema:PropertyValue
119 N0ecadb66ad9d48f79554241000712aa2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Female
121 rdf:type schema:DefinedTerm
122 N10b069ff09d64e1ea087a6b64cc33795 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
123 schema:name Male
124 rdf:type schema:DefinedTerm
125 N1423fe93fc37450a856fd313ba4b0a43 rdf:first sg:person.01007666002.23
126 rdf:rest Nf68daa1773e04885b6d8318e201173d0
127 N19a40581acf6468caa65d1df94aa1970 schema:name Springer Nature - SN SciGraph project
128 rdf:type schema:Organization
129 N27ac0466813e4484a77731dfad77b7c3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Follow-Up Studies
131 rdf:type schema:DefinedTerm
132 N50e78ad5218140c5955b5adbeacb3898 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Treatment Outcome
134 rdf:type schema:DefinedTerm
135 N53595b85f8ba45f59921ff46a4d1c514 rdf:first sg:person.01130633732.24
136 rdf:rest N1423fe93fc37450a856fd313ba4b0a43
137 N60d12dc01ca74ecdb35cbb1a50f2d6a6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Disease-Free Survival
139 rdf:type schema:DefinedTerm
140 N6147dc9d33124e08b3e0c5cf7b69ac48 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Dose-Response Relationship, Drug
142 rdf:type schema:DefinedTerm
143 N628a57780c9c46738bedd6f3c70ac083 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Drug Administration Schedule
145 rdf:type schema:DefinedTerm
146 N7001cd1a722142108b77d4b96915eccc schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
147 schema:name Humans
148 rdf:type schema:DefinedTerm
149 N719fe66593ac488a90ff44dfdff2cb1b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Aged
151 rdf:type schema:DefinedTerm
152 N76b36059dc1d4e45a04d388d7ed38ee6 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
153 schema:name Monoamine Oxidase Inhibitors
154 rdf:type schema:DefinedTerm
155 N79bb311c1a114ef395727c4aa33765dd schema:volumeNumber 24
156 rdf:type schema:PublicationVolume
157 N7c88b1f77b4b46e685dfd4add99aba14 rdf:first sg:person.0623540223.07
158 rdf:rest N53595b85f8ba45f59921ff46a4d1c514
159 N7d7f2f8467004a9bac5c89b48c797211 rdf:first sg:person.01013134010.15
160 rdf:rest Nb6f8b1d0ef2040149dc89e92b08372e2
161 N880c06bc8581472ab36404dd4d75f270 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
162 schema:name Adenocarcinoma
163 rdf:type schema:DefinedTerm
164 N89805d0f8ffc4120a63c7f75b4a01a8f rdf:first sg:person.010167317465.06
165 rdf:rest N9c62f0f9ab83412aaaebd5dd45d8f84b
166 N90cfcb34c656455ebc7b21bc1806fcef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Middle Aged
168 rdf:type schema:DefinedTerm
169 N9c62f0f9ab83412aaaebd5dd45d8f84b rdf:first sg:person.07360615242.02
170 rdf:rest rdf:nil
171 N9f95987868044268ab18694ed461b602 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
172 schema:name Biomarkers, Tumor
173 rdf:type schema:DefinedTerm
174 Na34ad9ea6e304504b8229ca60fe7e36a schema:name doi
175 schema:value 10.1038/s41391-020-0211-9
176 rdf:type schema:PropertyValue
177 Nb6f8b1d0ef2040149dc89e92b08372e2 rdf:first sg:person.015566147707.12
178 rdf:rest N89805d0f8ffc4120a63c7f75b4a01a8f
179 Nc3993d40cf0e42cb9174aec4067f32dd schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
180 schema:name Phenelzine
181 rdf:type schema:DefinedTerm
182 Nc5525a2ad0f64c19b36d89150d3de688 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
183 schema:name Neoplasm Staging
184 rdf:type schema:DefinedTerm
185 Nc9398808799e4e57898c88b6e3411dfb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Prostate-Specific Antigen
187 rdf:type schema:DefinedTerm
188 Nd9881e5a64bb460ca580213273b19440 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Prostatic Neoplasms
190 rdf:type schema:DefinedTerm
191 Ndfe7193278b748d89b72fd1ef0f5244f schema:issueNumber 1
192 rdf:type schema:PublicationIssue
193 Ned4c8512305d4b69b471c08850da91ad schema:name dimensions_id
194 schema:value pub.1125322716
195 rdf:type schema:PropertyValue
196 Nf68daa1773e04885b6d8318e201173d0 rdf:first sg:person.0600562331.16
197 rdf:rest N7d7f2f8467004a9bac5c89b48c797211
198 Nf8863eea5ce14ca885cac8b0331327ea schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Neoplasm Recurrence, Local
200 rdf:type schema:DefinedTerm
201 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
202 schema:name Medical and Health Sciences
203 rdf:type schema:DefinedTerm
204 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
205 schema:name Oncology and Carcinogenesis
206 rdf:type schema:DefinedTerm
207 sg:grant.2438805 http://pending.schema.org/fundedItem sg:pub.10.1038/s41391-020-0211-9
208 rdf:type schema:MonetaryGrant
209 sg:grant.5477093 http://pending.schema.org/fundedItem sg:pub.10.1038/s41391-020-0211-9
210 rdf:type schema:MonetaryGrant
211 sg:journal.1119336 schema:issn 1365-7852
212 1476-5608
213 schema:name Prostate Cancer and Prostatic Diseases
214 schema:publisher Springer Nature
215 rdf:type schema:Periodical
216 sg:person.01007666002.23 schema:affiliation grid-institutes:grid.42505.36
217 schema:familyName Dorff
218 schema:givenName Tanya B.
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01007666002.23
220 rdf:type schema:Person
221 sg:person.01013134010.15 schema:affiliation grid-institutes:grid.42505.36
222 schema:familyName Quinn
223 schema:givenName David I.
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01013134010.15
225 rdf:type schema:Person
226 sg:person.010167317465.06 schema:affiliation grid-institutes:grid.42505.36
227 schema:familyName Gilmore
228 schema:givenName Patrick
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010167317465.06
230 rdf:type schema:Person
231 sg:person.01130633732.24 schema:affiliation grid-institutes:grid.42505.36
232 schema:familyName Agus
233 schema:givenName David B.
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01130633732.24
235 rdf:type schema:Person
236 sg:person.015566147707.12 schema:affiliation grid-institutes:grid.42505.36
237 schema:familyName Castellanos
238 schema:givenName Olga
239 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015566147707.12
240 rdf:type schema:Person
241 sg:person.0600562331.16 schema:affiliation grid-institutes:grid.42505.36
242 schema:familyName Pinski
243 schema:givenName Jacek K.
244 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0600562331.16
245 rdf:type schema:Person
246 sg:person.0623540223.07 schema:affiliation grid-institutes:grid.42505.36
247 schema:familyName Gross
248 schema:givenName Mitchell E.
249 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0623540223.07
250 rdf:type schema:Person
251 sg:person.07360615242.02 schema:affiliation grid-institutes:grid.42505.36
252 schema:familyName Shih
253 schema:givenName Jean C.
254 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07360615242.02
255 rdf:type schema:Person
256 sg:pub.10.1038/nrn1883 schema:sameAs https://app.dimensions.ai/details/publication/pub.1004025765
257 https://doi.org/10.1038/nrn1883
258 rdf:type schema:CreativeWork
259 sg:pub.10.1038/s41388-018-0325-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1104267265
260 https://doi.org/10.1038/s41388-018-0325-x
261 rdf:type schema:CreativeWork
262 grid-institutes:grid.42505.36 schema:alternateName Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA, USA
263 Lawrence J. Ellison Institute for Transformative Medicine, University of Southern California, Los Angeles, CA, USA
264 Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
265 schema:name Department of Integrative Anatomical Sciences, University of Southern California, Los Angeles, CA, USA
266 Department of Medicine, University of Southern California, Los Angeles, CA, USA
267 Department of Pharmacology and Pharmaceutical Sciences, School of Pharmacy, University of Southern California, Los Angeles, CA, USA
268 Lawrence J. Ellison Institute for Transformative Medicine, University of Southern California, Los Angeles, CA, USA
269 Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA
270 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...